<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00863005</url>
  </required_header>
  <id_info>
    <org_study_id>K201-I/280301BS</org_study_id>
    <nct_id>NCT00863005</nct_id>
  </id_info>
  <brief_title>Assessment of the Effects on Barrier Impairment, Clinical Features and Bacterial Colonization of Topical Formulations in Patients With Atopic Eczema; a Phase IIa, Single-center, Randomized, Observer-blind Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Moberg Pharma AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Moberg Pharma AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is the assessment of the barrier impairment, clinical skin condition&#xD;
      and bacterial colonization status in patients with atopic eczema following topical treatment&#xD;
      with K201 cream and a comparator twice daily over a 4-week treatment period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
  </study_design_info>
  <primary_outcome>
    <measure>Transepidermal water loss (TEWL), clinical assessments, corneometry, bacterial counts</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>1. K201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>K201</intervention_name>
    <description>Cream</description>
    <arm_group_label>1. K201</arm_group_label>
    <arm_group_label>2.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>K201</intervention_name>
    <arm_group_label>1. K201</arm_group_label>
    <arm_group_label>2.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  signed written informed consent obtained;&#xD;
&#xD;
          -  male or female patients, 18 years or older;&#xD;
&#xD;
          -  manifest atopic eczema diagnosed according to Hanifin and Rajka;&#xD;
&#xD;
          -  two comparable lesional areas of 20 - 50 cm2 with a distance of at least 5 cm,&#xD;
             clinical condition of atopic eczema mild to moderate (meeting Hanifin and Rajka´s&#xD;
             criteria;&#xD;
&#xD;
          -  TEWL in the lesional areas at least 12 g/m²h, TEWL value differences ≤ 30 % are&#xD;
             allowed between both lesional areas;&#xD;
&#xD;
          -  the physical examination must be without disease findings unless the investigator&#xD;
             considers an abnormality to be irrelevant to the outcome of the study;&#xD;
&#xD;
          -  sexually active females of childbearing potential should either be surgically sterile&#xD;
             hysterectomy or tubal ligation), or should use a medically accepted contraceptive&#xD;
             regimen:systemic contraceptive (oral, implant, injection), diaphragm or cervical cap&#xD;
             with intravaginal spermicide, intrauterine device (IUD), condom with intravaginal&#xD;
             spermicide.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  acne, eczema other than atopic eczema, hyper- or hypopigmentation or tattoos in the&#xD;
             treatment areas;&#xD;
&#xD;
          -  suntan which in the opinion of the investigator prevents correct assessments&#xD;
&#xD;
          -  dark-skinned persons whose skin color prevents ready assessment of skin reactions;&#xD;
&#xD;
          -  evidence of drug or alcohol abuse;&#xD;
&#xD;
          -  pregnancy or nursing;&#xD;
&#xD;
          -  UV-therapy within 6 weeks before first treatment;&#xD;
&#xD;
          -  participation in another clinical study involving pharmaceutical products in the 28&#xD;
             days preceding or during the study;&#xD;
&#xD;
          -  symptoms of a clinically significant illness that may influence the outcome of the&#xD;
             study in the four weeks before and during the study;&#xD;
&#xD;
          -  known allergic reactions to components of the study preparation and the comparator;&#xD;
&#xD;
          -  treatment with systemic or locally acting medications which might counter or influence&#xD;
             the study aim (e.g. antihistamines or glucocorticosteroids) within two weeks before&#xD;
             the beginning of the study (exception: asthma may be found in patients with atopic&#xD;
             eczema,therefore inhalation with corticosteroids in patients with asthma accompanying&#xD;
             atopic eczema will be allowed at a dose not exceeding 1 mg/day. The dosage should&#xD;
             remain constant throughout the study period);&#xD;
&#xD;
          -  in the opinion of the investigator or physician performing the initial examination the&#xD;
             patient should not participate in the study, e.g. due to probable noncompliance or&#xD;
             inability to understand the study and give adequately informed consent;&#xD;
&#xD;
          -  patient is institutionalized because of legal or regulatory order.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>bioskin GmbH</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <study_first_submitted>March 12, 2009</study_first_submitted>
  <study_first_submitted_qc>March 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2009</study_first_posted>
  <last_update_submitted>November 5, 2009</last_update_submitted>
  <last_update_submitted_qc>November 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

